5 & # 39; December 2018 – 16:45
Researchers at the Massachusetts Institute of Technology (MIT) in & # 39; Cambridge, USA, have developed a new experimental approach that allows anti-osteoarthritis drug enters the articular cartilage tirriġeneraha.
Researchers at the Massachusetts Institute of Technology (MIT) in & # 39; Cambridge, USA, have developed a new experimental approach that allows anti-osteoarthritis drug enters the articular cartilage tirriġeneraha. The advance is being tested in rats and is a step & # 39; ahead to achieve treatment slows the progression of & # 39; this disease, which m & # 39; there is no cure.
The artrosi consists & # 39; progressive degeneration of articular cartilage due to aging or injury. This pathology affects 300 million people worldwide and m & # 39; has no reverse, because cartilage is a tissue that can not regenerate.
According to this, patients may choose to undergo surgery to introduce prosthesis in the affected joint or follow pharmacological treatment, but the counterpart is that it is very difficult to have access to the cartilage.
The majority of drugs removed from the joints before they can take effect or may not penetrate into the cartilage, where the cells that produce it – the chondrocytes – found, so that they can perform their function .
Researchers led by MIT strategy sought to overcome this hurdle. They have designed nanocarrier: a molecule that acts as a vehicle able to enter into the cartilage and chondrocytes to take medicine. The molecule consists & # 39; spherical part with binding drug, structures such as branches b & # 39; and positive electrical charge compound called PEG.
Since cartilage has a negative weight, the positive charges of causing nanocarrier with tissue adhesive. PEG, on the other hand, allows cut & # 39; the cartilage and reach citizens, ċekondroċiti.
According to the newspaper La VANGUARDIA, to begin publication of the Science journal Translational Medicine, scientists increased the nanocarrier drug called IGF-1, which stimulates the production of cartilage and survival and the chondrocytes growth.
To test the strategy, injected the drug nanocarrier in joints & # 39; the knee & # 39; rats had osteoarthritis from injury. The treatment reduced cartilage destruction, inflammation and the appearance & # 39; bone alterations related osteoarthritis. Compared to & # 39; injection & # 39; IGF-1, the only combination with the nanocarrier multiplied by & # 39; ten half-life of the drug in the joints. In addition, it was maintained at & # 39; effective concentrations cartilage for thirty days, thus potentially injection & # 39; every two weeks or every month is enough.
Source: La Nacion